Polio Virus May Help Fight Brain Tumors

Opinions

Editorial Staff Whealthnews

Date: 04.07.2018

An ancient scourge -- the poliovirus -- may be an unexpected friend to people battling one of the deadliest brain cancers, new research shows.

The new therapy uses a tweaked, harmless form of the polio virus to significantly boost the chances patients with recurrent glioblastomas can survive over the long term.

In the study from Duke University in Durham, N.C., 21 percent of patients who got the new treatment were still alive three years later, compared to just 4 percent of those who received standard therapy.

"There is a tremendous need for fundamentally different approaches," study senior author Dr. Darell Bigner, emeritus director of Duke's brain tumorcenter, said in a university news release. "With the survival rates in this early phase of the polio virus therapy, we are encouraged and eager to continue with the additional studies that are already underway or planned."

Brain cancer expert Dr. Michael Schulder noted that the "results from this trial have been eagerly awaited after preliminary information was announced on 60 Minutes several years ago."

He helps direct neurosurgery at North Shore University Hospital in Manhasset, N.Y., but wasn't involved in the new trial.

The data on outcomes from the new study remain somewhat incomplete, Schulder said, so "we will have to await the availability of the full paper to assess the effectiveness of this new treatment for patients with glioblastoma."

As the Duke team explained, the new approach uses an altered, harmless form of the polio virus to target and destroy glioblastoma cells while triggering a powerful immune response.

The initial study included 61 patients who received the genetically modified polio virus developed at the Duke Cancer Institute. Their outcomes were compared to the records of previous patients who had received standard treatment.

Median overall survival was 12.5 months in the polio virus group and 11.3 months in the control group. But the gap between treatments widened for patients who lived longer, Bigner's group noted.

Survival rates at two years were 21 percent in the polio virus group and 14 percent in the group that didn't get the therapy, and at three years they were 21 percent and 4 percent, respectively.

Views: 906

Leave a request

Select option
Thank you, application submitted.